Atherosclerotic Cardiovascular Disease
Lower target LDL after stroke prevents 25% of events at 5 years
During the 5 years after a stroke, targeting LDL of less than 70 mg/dL prevented more than one-quarter of major CV events, recurrent cerebral infarction or urgent carotid revascularization and recurrent cerebral infarction or hemorrhage vs. an LDL target of less than approximately 100 mg/dL.
Physical inactivity confers similar ASCVD risk to smoking status
Physical inactivity was associated with an excess risk for atherosclerotic CVD similar to smoking and poor cholesterol levels, according to a research letter published in the European Journal of Preventive Cardiology.
Large waist circumference increases recurrent event risk after MI
Abdominal obesity was common in patients post-MI, and a larger waist circumference in this population was independently linked with recurrent atherosclerotic CVD, especially in men, according to a study published in the European Journal of Preventive Cardiology.
Novel score may predict CV event risk similarly to ASCVD risk score
A novel score to predict 10-year risk for incident CV events using patient-reported information was comparable to the atherosclerotic CVD risk score, according to a study published in the Journal of the American Heart Association.
Differences in dyslipidemia guidelines underscore complexity of CVD prevention
The cornerstone of CV prevention is risk assessment because patients at higher risk for atherosclerotic events typically derive a higher absolute benefit from preventive therapies.
Can green tea prevent atherosclerotic CVD? Read the week’s top stories in cardiology
Green tea may lower risk for ASCVD, mortality in Chinese population
Habitual drinking of tea, particularly green tea, confers a significant reduction in risk for atherosclerotic CVD and all-cause mortality, according to research published in the European Journal of Preventive Cardiology.
Icosapent ethyl may act on plaque
A potential target for improving residual lipid-related risk for atherosclerotic CVD is reduction in triglyceride levels. Studies have shown eicosapentaenoic acid is effective in lowering triglyceride levels and reducing the risk for ischemic events in patients with elevated triglyceride levels already taking statin therapy.
ORION-10
Safety, efficacy and tolerability of inclisiran (The Medicines Company) in patients with atherosclerotic CVD and elevated LDL despite optimal medical therapy.
High CVD risk confers greater odds of cancer
PHILADELPHIA — People at high risk for CVD, as assessed by risk factors, 10-year atherosclerotic CVD risk score and biomarkers, also have elevated risk for cancer, according to research presented at the American Heart Association Scientific Sessions.